Prostate Cancer

Age-adjusted Charlson Comorbidity Index as a prognostic factor for radical prostatectomy outcomes of very high-risk prostate cancer patients.

Prostate cancer (PC) is a devastating and heterogeneous condition with diverse treatment options. When selecting treatments for patients with very high-risk PC, clinicians must consider patient comorbidities.

MR diffusion kurtosis imaging for cancer diagnosis: A meta-analysis of the diagnostic accuracy of quantitative kurtosis value and diffusion coefficient.

To perform a meta-analysis for assessing the accuracy of diffusion kurtosis imaging (DKI)-derived quantitative parameters (kurtosis values, K; and corrected diffusion coefficients non-Gaussian bias, D) in separating malignant cancers from benign lesions.

An Automated Multiparametric MRI Quantitative Imaging Prostate Habitat Risk Scoring System for Defining External Beam Radiotherapy Boost Volumes.

To develop a prostate tumor habitat risk scoring (HRS) system based on multiparametric MRI (mpMRI) referenced to prostatectomy Gleason Score (GS) for automatic delineation of Gross Tumor Volumes (GTVs).

Repositioning Dopamine D2 Receptor Agonist Bromocriptine to Enhance Docetaxel Chemotherapy and Treat Bone Metastatic Prostate Cancer.

Docetaxel resistance remains a major obstacle in the treatment of prostate cancer (PCa) bone metastasis. In this study, we demonstrate that the dopamine D2 receptor (DRD2) agonist bromocriptine effectively enhances docetaxel efficacy and suppresses skeletal growth of PCa in preclinical models.

Interrupted versus Continuous Suturing for Vesicourethral Anastomosis During Radical Prostatectomy: A Systematic Review and Meta-analysis.

Vesicourethral anastomosis (VUA) is a crucial step during radical prostatectomy (RP). Generally, either a continuous (CS) or an interrupted suture (IS) is used. However, there is no clear evidence if one technique is superior to the other.

Toward planning target volume margin reduction for the prostate using intrafraction motion correction with online kV imaging and automatic detection of implanted gold seeds.

The imaging application Auto Beam Hold (ABH) allows for the online analysis of 2-dimensional kV images acquired during treatment. ABH can automatically detect fiducial markers and initiate a beam interrupt.

Describing Perspectives of Health Care Professionals on Active Surveillance for the Management of Prostate Cancer - Beyond the Abstract

When diagnosed with low-risk prostate cancer, men are involved in the decision about active surveillance as an option for disease management. They are asked to learn about the disease and different treatment options during a time of distress and to embark on a course of action that may counter their expectations. We investigated how men made their decisions and interrogated their conversations with physicians about their choices. We sought to understand how clinicians approached these conversations since the practice involving discussions about active surveillance is not yet defined and is still developing. These conversations are critical for helping men to understand the situation and the emerging evidence, and to facilitate an informed decision about active surveillance.

Impact of 68Ga-PSMA PET on the Management of Patients with Prostate Cancer - Beyond the Abstract

Prostate cancer is one of the most common cancers in men [1]. Various imaging modalities have been used to assess the presence and extent of primary or recurrent tumors, however, at least partly due to prostate cancer’s predilection for metastatic spread to bone, their suboptimal diagnostic capability has been well documented. The prostate-specific membrane antigen (PSMA), which is a protein expressed on dysplastic prostate cells, has been a target of interest to cancer biologists and imagers for several decades. Novel positron emission tomography (PET) imaging probes targeting the internal epitope of the PSMA receptor have shown great potential to overcome some of the difficulties in this field. PSMA is expressed in prostate cancer cells at 100–1000 times higher levels than that of normal prostate cells and with an even greater degree in tumors with higher stages and grades [2]. Studies have shown that 68Ga-PSMA PET has excellent ability to detect lesions, even in patients with low serum PSA levels, and that this may affect patient management.

Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.

Using integrative genomic analysis of 360 metastatic castration-resistant prostate cancer (mCRPC) samples, we identified a novel subtype of prostate cancer typified by biallelic loss of CDK12 that is mutually exclusive with tumors driven by DNA repair deficiency, ETS fusions, and SPOP mutations.

The Association of Previous Prostate Biopsy-Related Complications and the Type of Complication with Patient Compliance with Re-Biopsy Scheme.

Prostate biopsy complications have important consequences that may affect patient compliance with re-biopsy schemes; however, this has not been studied in earnest. Thus, we evaluated whether previous prostate biopsy-related complications and the type of complication were associated with repeat prostate biopsy compliance in a clinical trial with study-mandated systematic biopsies.